Fluicell AB (publ) (Fluicell AB) aksje

Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration. It also provides Biopixlar, a 3D single-cell bioprinting platform that produces single cell arrays to organoids and complex tissues; Nexocyte, a platform for universal tissue production; and Biopixlar AER, a single-cell bioprinting platform that fits into a biosafety cabinet. Fluicell AB (publ) was incorporated in 2012 and is based in Mölndal, Sweden.